~6667 spots leftby May 2043

Biomarker Study for Cancer

Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Audubon Bioscience
No Placebo Group

Trial Summary

What is the purpose of this trial?

Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations. The Study is designed to discover biomarkers, develop and validate diagnostic assays, instruments and therapeutics as well as other medical research. Specifically, researchers may analyze proteins, RNA, DNA copy number changes, including large and small (1,000-100,000 kb) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both diseased tissue and case-matched germline DNA from Subjects.

Eligibility Criteria

This study is for individuals aged 20-39 or 70-79 who identify as Caucasian/Non-Hispanic and are citizens of the US or Canada. Participants should generally be in good health, without any specific medical conditions mentioned.

Inclusion Criteria

Are you between the ages of 80-89?
In general, would you consider yourself to be in good health?
Are you a citizen of the United States or Canada?
See 1 more

Treatment Details

Trial OverviewThe trial is an observational study with no interventions. It aims to discover biomarkers by analyzing a wide range of biological materials like proteins and DNA from both healthy people and those with various diseases.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Subjects with various conditionsExperimental Treatment1 Intervention
Subjects that have been diagnosed with a condition of interest such as Diabetes, NASH, Breast Cancer, Endometriosis, or other designated condition.
Group II: HealthyExperimental Treatment1 Intervention
Healthy subjects with no history of chronic disease

Find a Clinic Near You

Who Is Running the Clinical Trial?

Audubon Bioscience

Lead Sponsor

Trials
1
Recruited
10,000+